Tempus AI is a publicly traded health technology company founded in 2015 by Groupon co-founder Eric Lefkofsky. Based in Chicago, Tempus maintains one of the world largest libraries of clinical and molecular data, combining genomic sequencing with clinical patient histories using machine learning models to give oncologists and cardiologists data-driven insights for personalized therapy selection.
The company core offering integrates two data types that have historically been siloed: genomic sequencing data that reveals the molecular drivers of a patient disease, and clinical data that captures the patient treatment history, outcomes, and demographic characteristics. By analyzing these datasets together, Tempus AI can identify patterns that would be invisible to clinicians reviewing either dataset in isolation.
Tempus went public in 2024 and has continued to expand its platform through acquisitions and partnerships. The company platform is used by a majority of U.S. academic medical centers and community oncology practices, making it one of the most widely deployed precision medicine platforms in clinical use. The company has also expanded into cardiology, applying its data integration and machine learning approach to cardiovascular disease.
The competitive landscape for precision medicine AI includes Foundation Medicine, Guardant Health, and Caris Life Sciences. Tempus differentiation lies in its comprehensive data library and its ability to integrate clinical and molecular data at scale. The company has invested heavily in building the infrastructure to collect, standardize, and analyze clinical data from diverse EHR systems, creating a data asset that competitors cannot easily replicate.
Tempus business model combines diagnostic testing revenue with data licensing and software subscriptions. The company generates revenue from its genomic testing services while also licensing its de-identified data to pharmaceutical companies for drug development and clinical trial matching. This dual revenue stream has supported the company growth and investment in its technology platform.
The broader context for Tempus success is the accelerating integration of commercial AI platforms across healthcare, where data-driven precision medicine is becoming standard of care for an increasing number of cancer types. Tempus platform is also relevant to the advances in targeted cancer therapies, where genomic profiling is essential for matching patients to the most effective treatments.
Tempus has also invested in building clinical trial matching capabilities, using its data platform to identify patients who may be eligible for specific clinical trials based on their genomic and clinical profiles. This capability addresses a significant bottleneck in cancer research: the difficulty of identifying and enrolling patients with specific molecular characteristics. By automating the matching process, Tempus helps accelerate the development of new cancer therapies.
The company has expanded beyond oncology into cardiology and neurology, applying its data integration and machine learning approach to cardiovascular disease and neurological conditions. This expansion reflects the broader potential of precision medicine approaches across multiple disease areas. The compute infrastructure required for genomic analysis is substantial, and Tempus has invested heavily in the data center capacity needed to process its growing genomic and clinical datasets.